Literature DB >> 20221877

Anti-inflammatory properties of paraoxonase-1 in atherosclerosis.

Bharti Mackness1, Mike Mackness.   

Abstract

Atherosclerosis is increasingly recognised as an inflammatory disease. The inflammatory process begins with the oxidation of low-density lipoprotein (LDL) in the artery wall. The ability of high-density lipoprotein (HDL) to inhibit the oxidation of LDL (and cell membranes) and promote macrophage cholesterol efflux through the action of several of its associated proteins, particularly paraoxonase-1 (PON1), reduces the inflammation associated with atherosclerosis. In vivo, in animal models, ablation of the PON1 gene is pro-inflammatory and pro-atherogenic, while overexpression of human PON1 is anti-inflammatory and anti-atherogenic. In subjects with diabetes mellitus, PON1 is dysfunctional due to glycation, reducing its ability to retard LDL and cell membrane oxidation and contributing to the inflammation typical of diabetes, leading to the excess atherosclerosis common in this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221877     DOI: 10.1007/978-1-60761-350-3_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  38 in total

Review 1.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 2.  Paraoxonases: metabolic role and pharmacological projection.

Authors:  Carlos Moya; Salvador Máñez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-06       Impact factor: 3.000

Review 3.  HDL--is it too big to fail?

Authors:  Dominic S Ng; Norman C W Wong; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2013-01-15       Impact factor: 43.330

4.  Regulation of paraoxonase 1 (PON1) in PCB 126-exposed male Sprague Dawley rats.

Authors:  Hua Shen; Larry W Robertson; Gabriele Ludewig
Journal:  Toxicol Lett       Date:  2012-01-12       Impact factor: 4.372

5.  Antioxidant and lipid-regulating effects of probucol combined with atorvastatin in patients with acute coronary syndrome.

Authors:  Yu-Song Guo; Cai-Xia Wang; Jian Cao; Jin-Liao Gao; Xiao Zou; Yi-Hong Ren; Li Fan
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

6.  A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice.

Authors:  Yanyong Xu; Hongmei Liu; Mengting Liu; Feifei Li; Liangchen Liu; Fen Du; Daping Fan; Hong Yu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

Review 7.  Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins.

Authors:  Baiba K Gillard; Corina Rosales; Bingqing Xu; Antonio M Gotto; Henry J Pownall
Journal:  J Clin Lipidol       Date:  2018-04-12       Impact factor: 4.766

8.  Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role.

Authors:  Fernando Rodríguez-Sanabria; Anna Rull; Raúl Beltrán-Debón; Gerard Aragonès; Jordi Camps; Bharti Mackness; Michael Mackness; Jorge Joven
Journal:  J Mol Histol       Date:  2010-10-08       Impact factor: 2.611

9.  Evidence for the presence of active paraoxonase 1 in small-dense low-density lipoprotein.

Authors:  Alejandro Gugliucci; Russell Caccavello; Kazuhiko Kotani; Satoshi Kimura
Journal:  Redox Rep       Date:  2014-02-14       Impact factor: 4.412

10.  High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography.

Authors:  Scott M Gordon; Jonathan H Chung; Martin P Playford; Amit K Dey; Denis Sviridov; Fayaz Seifuddin; Yun-Ching Chen; Mehdi Pirooznia; Marcus Y Chen; Nehal N Mehta; Alan T Remaley
Journal:  Atherosclerosis       Date:  2018-09-25       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.